Sankaran Deepa, Bankovic-Calic Neda, Cahill Leah, Yu-Chen Peng Claudia, Ogborn Malcolm R, Aukema Harold M
Departments of Human Nutritional Sciences, University of Manitoba, Winnipeg, Man., Canada.
Nephron Exp Nephrol. 2007;106(4):e122-8. doi: 10.1159/000104836. Epub 2007 Jun 29.
BACKGROUND/AIMS: Dietary soy protein and flax oil retard kidney disease progression when initiated in the early stages of disease in several experimental models, including the Han:SPRD-cy rat. However, individuals with kidney disease often do not become aware of their condition until injury to the kidney is extensive. The objective of this study was to determine whether initiating these interventions in established disease would alter further progression of renal injury.
Two-month-old adult male Han:SPRD-cy rats were given either a flax oil diet (7% flax oil), a soy protein diet (20% soy protein) or a control diet (7% corn oil, 20% casein) for 4 months. Renal disease progression was assessed by examining morphological, immunohistochemical and biochemical parameters.
Compared to controls, there was 21-24% less staining of proliferating cells, 21-24% less oxidative damage and 13-15% less renal inflammation in kidneys from rats given dietary soy protein and flax oil. Renal cystic growth and fibrosis and serum creatinine levels were not altered by these dietary treatments.
Late intervention with dietary soy protein and flax oil reduces some disease-associated pathologies in established renal disease in Han:SPRD-cy rats. The potential benefits of the antioxidant and anti-inflammatory effects on ultimate renal disease outcome in the long term remains to be determined.
背景/目的：在包括Han:SPRD-cy大鼠在内的几种实验模型中，在疾病早期开始摄入膳食大豆蛋白和亚麻油可延缓肾脏疾病进展。然而，肾病患者往往直到肾脏受到广泛损伤才意识到自己的病情。本研究的目的是确定在已确诊的疾病中开始这些干预措施是否会改变肾损伤的进一步进展。
给2个月大的成年雄性Han:SPRD-cy大鼠喂食亚麻油饮食（7%亚麻油）、大豆蛋白饮食（20%大豆蛋白）或对照饮食（7%玉米油，20%酪蛋白），持续4个月。通过检查形态学、免疫组织化学和生化参数评估肾脏疾病进展。
与对照组相比，摄入膳食大豆蛋白和亚麻油的大鼠肾脏中增殖细胞染色减少21%-24%，氧化损伤减少21%-24%，肾脏炎症减少13%-15%。这些饮食处理未改变肾囊肿生长、纤维化和血清肌酐水平。
在Han:SPRD-cy大鼠已确诊的肾脏疾病中，晚期采用膳食大豆蛋白和亚麻油干预可减少一些与疾病相关的病理变化。抗氧化和抗炎作用对最终肾脏疾病结局的潜在益处长期来看仍有待确定。
